A comparative study of the effects of selective and non-selective 5- HT2 receptor subtype antagonists in rat and mouse models of anxiety

Neuropharmacology

Volumn 36, Issue 6, 1997, Pages 793-802

  Griebel, G ^a   Perrault, G ^a   Sanger, D J ^a  

^a SANOFI   (France)

Author keywords

5 HT2 receptor antagonists; Anxiety; Elevated plus maze; Light dark choice test; MDL 100,907; Mianserin; Mouse defense test battery (MDTB); SB 206553; Vogel drinking test

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; MIANSERIN; RECEPTOR SUBTYPE; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DRINKING; FLUOROBENZENES; INDOLES; MALE; MAZE LEARNING; MIANSERIN; MICE; MICE, INBRED BALB C; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0030876913     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00034-8     Document Type: Article

References (63)

1. Barnes N. M., Cheng C. H., Costall B., Ge J., Kelly M. E. and Naylor R. J. (1992) Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model. Eur. J. Pharmacol. 218: 91-100.
2. 2 receptor subtypes: a family re-united? Trends Pharmacol. Sci. 16: 105-110.
3. 2B receptors. Behav. Brain Res. 73: 149-152.
4. Belzung C., Pineau N., Beuzen A. and Misslin R. (1994) PD135158, a CCK-B antagonist, reduces "state", but not "trait" anxiety in mice. Pharmacol. Biochem. Behav. 49: 433-436.
5. Ceulemans D. L., Hoppenbrouwers M. L., Gelders Y. G. and Reyntjens A. J. (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303-305.
6. Charney D. S., Woods S. W., Goodman W. K. and Heninger G. R. (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92: 14-24.
7. Cole J. C. and Rodgers R. J. (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4: 573-580.
8. Cole J. C. and Rodgers R. J. (1994) Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 114: 288-296.
9. Colpaert F. C., Meert T. F., Niemegeers C. J. and Janssen P. A. (1985) Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 86: 45-54.
10. Costall B., Kelly M. E., Naylor R. J. and Onaivi E. S. (1988) Actions of buspirone in a putative model of anxiety in the mouse. J. Pharm. Pharmacol. 40: 494-500.
11. Cruz A. P. M., Frei F. and Graeff F. G. (1994) Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49: 171-176.
12. Den Boer J. A. and Westenberg H. G. (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102: 85-94.
13. 2B receptor protein in the rat brain. Br. J. Pharmacol. 115: 105P.
14. 1A receptor in the anxiolytic action of indorenate and ipsapirone. Psychopharmacology 101: 354-358.
15. 2B receptor mRNA in rat brain. Br. J. Pharmacol. 114: 369P.
16. 2C receptor antagonist with improved potency, selectivity and oral activity. J. Med. Chem. 38: 2524-2530.
17. 1C receptor antagonist. J. Med. Chem. 36: 1104-1107.
18. Gao B. and Cutler M. G. (1993) Effects of acute and subchronic administration of ritanserin on the social behaviour of mice. Neuropharmacology 32: 265-272.
19. Griebel G. (1993) Système sérotoninergique et réactivité émotionnelle chez le rat et chez la souris. Approche pharmacologique. Thesis, Université Louis Pasteur, Strasbourg.
20. Griebel G. (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther. 65: 319-395.
21. Griebel G., Blanchard D. C., Agnes R. S. and Blanchard R. J. (1995a) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120: 57-66.
22. Griebel G., Blanchard D. C., Jung A. and Blanchard R. J. (1995b) A model of "antipredator" defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav. Pharmacol. 6: 732-745.
23. Griebel G., Blanchard D. C., Jung A., Lee J. C., Masuda C. K. and Blanchard R. J. (1995c) Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology 34: 1625-1633.
24. 2A antagonist pirenperone. Pharmacol. Biochem. Behav. 51: 235-244.
25. 1A agonist, S20244, and its enantiomers in mice. Neuroreport 3: 84-86.
26. Griebel G., Rodgers R. J., Sanger D. J. and Perrault G. (1995) Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol. Biochem. Behav. In press.
27. Griebel G., Sanger D. J. and Perrault G. (1996a) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology 124: 245-254.
28. Griebel G., Sanger D. J. and Perrault G. (1996b) Further evidence for differences between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands in murine models of state and trait anxiety. Neuropharmacology 35: 1081-1091.
29. Handley S. L. and McBlane J. W. (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Meth. 29: 129-138.
30. Hogg S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54: 21-30.
31. Humble M., Asberg-Wistedt A., Wistedt B. and Bertilsson L. (1986) A pilot study of ritanserin (a selective serotonin-2 receptor antagonist) in panic disorder and agoraphobia. Clinical and biochemical effects. C.I.N.P. Congress, Puerto Rico, p. 165.
32. Imaizumi M., Miyazaki S. and Onodera K. (1994) Effects of xanthine derivatives in a light dark test in mice and the contribution of adenosine receptors. Meth. Find. Exp. Clin. Pharmacol. 16: 639-644.
33. Jain N., Kemp N., Adeyemo O., Buchanan P. and Stone T. W. (1995) Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116: 2127-2133.
34. Kahn R. S., Wetzler S., Van Praag H. M., Asnis G. M. and Strauman T. (1988) Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiat. Res. 25: 101-104.
35. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology 118: 178-182.
36. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology 114: 90-96.
37. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 117: 427-434.
38. 2C/2B receptor antagonist. Br. J. Pharmacol. 111: 797-802.
39. 2F) from rat stomach fundus. Molec. Pharmacol. 42: 549-557.
40. Lister R. G. (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185.
41. Lopez-Rubalcava C., Saldivar A. and Fernandez-Guasti A. (1992) Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics. Pharmacol. Biochem. Behav. 43: 433-440.
42. 2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 312: 203-207.
43. Misslin R., Belzung C. and Vogel E. (1989) Behavioural validation of a light/dark choice procedure for testing antianxiety agents. Behav. Process. 8: 119-132.
44. 1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. Neuroreport 1: 267-270.
45. 1A receptor antagonist (5)-UH-301 in rodents and monkeys. Brain Res. Bull. 29: 901-904.
46. 2A antagonist. Behav. Brain Res. 73: 163-167.
47. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology 107: 135-139.
48. Mueller E. A., Murphy D. L. and Sunderland T. (1985) Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. J. Clin. Endocrinol. Metab. 61: 1179-1184.
49. Pellow S., Chopin P., File S. E. and Briley M. (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14: 149-167.
50. Rodgers R. J. and Cole J. C. (1994a) The elevated plus-maze: pharmacology, methodology and ethology. In: Ethology and Psychopharmacology (Cooper S. J. and Hendrie C. A., Eds), pp. 9-44. John Wiley, Chichester.
51. 1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 261: 321-325.
52. Rodgers R. J., Cole J. C., Cobain M. R. and Daly P. (1992) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B. TFMPP and mCPP. Behav. Pharmacol. 3: 621-634.
53. 1A receptor agonist, flesinoxan. Pharmacol. Biochem. Behav. 48: 959-963.
54. Rodgers R. J., Johnson N. J. T., Norton S. J. and Cole J. C. (1995) Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: an ethopharmacological study. J. Psychopharmacol 9: 38-42.
55. Sanchez C., Arnt J., Costall B., Domeney A. M., Kelly E. and Naylor R. J. (1995) Sertindole: a limbic selective neuroleptic with potent anxiolytic effects. Drug Develop. Res. 34: 19-29.
56. Schreiber R., Brocco M. and Millan M. J. (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the "atypical" antipsychotics, clozapine and risperidone. Eur. J. Pharmacol. 264: 99-102.
57. Sevy S., Brown S. L., Wetzler S., Kotler M., Molcho A., Plutchik R. and Van praag H. M. (1994) Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiat. Res. 53: 219-229.
58. Svartengren J. and Simonsson P. (1990) Receptor binding properties of amperozide. Pharmacol. Toxicol. 66 (Suppl. 1):8-11.
59. Treit D. (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9: 203-222.
60. Vogel J. R., Beer B. and Clody D. E. (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21: 1-7.
61. Westenberg H. G. and Den Boer J. A. (1989) Serotonin-influencing drugs in the treatment of panic disorder. Psychopathology 22 (Suppl. 1): 68-77.
62. Willard M., Misslin R., Vogel E., Desaubry L., Wermuth C. G. and Bourguignon J. J. (1990) Anxiolytic and sedative properties of BW A78U, a novel anticonvulsant adenine derivative. Pharmacol. Biochem. Behav. 35: 85-88.
63. Witkin J. M. and Perez L. A. (1990) Comparison of effects of buspirone and gepirone with benzodiazepines and antagonists of dopamine and serotonin receptors on punished behavior of rats. Behav. Pharmacol. 1: 247-254.